ACS Chemical Neuroscience
Letter
(12) Chatterjie, N., Sechzer, J. A., Lieberman, K. W., and Alexander,
G. J. (1998) Dextro-Naloxone Counteracts Amphetamine-Induced
Hyperactivity. Pharmacol., Biochem. Behav. 59 (2), 271−274.
(13) Wu, H.-e., Hong, J.-S., and Tseng, L. F. (2007) Stereoselective
action of (+)-morphine over (−)-morphine in attenuating the
(−)-morphine-produced antinociception via the naloxone-sensitive
sigma receptor in the mouse. Eur. J. Pharmacol. 571, 145−151.
(14) Hutchinson, M. R., Northcutt, A. L., Hiranita, T., Wang, X.,
Lewis, S. S., Thomas, J., van Steeg, K., Kopajtic, T. A., Loram, L. C.,
Sfregola, C., Galer, E., Miles, N. E., Bland, S. T., Amat, J., Rozeske, R.
R., Maslanik, T., Chapman, T. R., Strand, K. A., Fleshner, M., Bachtell,
R. K., Somogyi, A. A., Yin, H., Katz, J. L., Rice, K. C., Maier, S. F., and
Watkins, L. R. (2012) Opioid Activation of Toll-Like Receptor 4
Contributes to Drug Reinforcement. J. Neurosci. 32 (33), 11187−
11200.
ACKNOWLEDGMENTS
■
Brettphos mesylate precatalyst was generously provided by
Professor Stephen Buchwald. The assistance of Mr. Lucas
Morrill in the preparation of dextrorotatory intermediates is
gratefully acknowledged. Ki determinations for NMDA, σ1, and
σ2 were generously provided by the National Institute of
Mental Health’s Psychoactive Drug Screening Program,
Contract # HHSN-271-2008-00025-C (NIMH PDSP). The
NIMH PDSP is Directed by Bryan L. Roth MD, PhD at the
University of North Carolina at Chapel Hill and Project Officer
Jamie Driscol at NIMH, Bethesda MD, USA. For experimental
edu/ and click on “JBinding Assay” or “Functional Assay” on
the menu bar (experimental details have been updated!).
(15) (a) Neumeyer, J. L., Bidlack, J. M., Zong, R., Bakthavachalam,
V., Gao, P., Cohen, D. J., Negus, S. S., and Mello, N. K. (2000)
Synthesis and Opioid Receptor Affinity of Morphinan and
Benzomorphan Derivatives: Mixed κ Agonists and μ Agonists/
Antagonists as Potential Pharmacotherapeutics for Cocaine Depend-
ence. J. Med. Chem. 43, 114−120. (b) Neumeyer, J. L., Negus, S. S.,
and Bidlack, J. M. (2000) Kappa Opioid Agonists as Targets for
Pharmacotherapies in Cocaine Abuse. Pharm. Acta. Helv. 74, 337−344.
(c) Bowen, C. A., Negus, S. S., Zong, R., Neumeyer, J. L., Bidlack, J.
M., and Mello, N. K. (2003) Effects of Mixed-Action Kappa/Mu
Opioids on Cocaine Self-Administration and Cocaine Discrimination
by Rhesus Monkeys. Neuropsychopharmacology 28, 1125−1139.
(d) Zhang, A., Vliet, S. V., and Neumeyer, J. L. (2003) Synthesis of
aminothiazole derived morphinans. Tetrahedron Lett. 44, 6459−6462.
(e) Decker, M., Si, Y. G., Knapp, B. I., Bidlack, J. M., and Neumeyer, J.
L. (2010) Synthesis and Opioid Receptor Binding Affinities of 2-
Substituted and 3-Aminomorphinans: Ligands for μ, κ, and δ Opioid
Receptors. J. Med. Chem. 53, 402−418.
(16) Kim, H.-C., Nabeshima, T., Jhoo, W.-K., Ko, K. H., Kim, W.-K.,
Shin, E.-J., Cho, M., and Lee, P. H. (2001) Anticonvulsant Effects of
New Morphinan Derivatives. Bioorg. Med. Chem. Lett. 11, 1651−1654.
(17) Peng, X., Knapp, B. I., Bidlack, J. M., and Neumeyer, J. L. (2006)
Synthesis and Preliminary In vitro Investigation of Bivalent Ligands
Containing Homo- and Heterodimeric Pharmacophores at μ, δ, and κ
Opioid Receptors. J. Med. Chem. 49, 256−262.
(18) Stringer, M., Makin, M. K., Miles, J., and Morley, J. S. (2000) d-
Morphine, but not l-morphine, has low micromolar affinity for the
non-competitive N-methyl-D-aspartate site in rat forebrain. Possible
clinical implications for the management of neuropathic pain. Neurosci.
Lett. 295, 21−24.
(19) Codd, E. E., Shank, R. P., Schupsky, J. J., and Raffa, R. B. (1995)
Serotonin and Norepinephrine Uptake Inhibiting Activity of Centrally
Acting Analgesics: Structural Determinants and role in Antinocicep-
tion. J. Pharmacol. Exp. Ther. 274, 1263−1270.
(20) Kroemer, R. T., Koutsilieri, E., Hecht, P., Leidl, K. R., Riederer,
P., and Kornhuber, J. (1998) Quantitative Analysis of the Structural
Requirements for the Blockade of the N-Methyl-D-aspartate Receptor
at the Phencyclidine Binding Site. J. Med. Chem. 41, 393−400.
(21) Chou, Y.-C., Liao, J.-F., Chang, W.-Y., Lin, M.-F., and Chen, C.-
F. (1999) Binding of dimemorphan to sigma-1 receptor and its
anticonvulsant and locomotor effects in mice, compared with
dextromethorphan and dextrorphan. Brain Res. 821, 5116−519.
(22) Knoll, A. T., and Carlezon, W. A., Jr. (2010) Dynorphin, stress,
and depression. Brain Res. 1314, 56−73.
(23) Tomasiewicz, H. C., Todtenkopf, M. S., Chartoff, E. H., Cohen,
B. M., and Carlezon, W. A., Jr. (2008) The kappa-opioid agonist
U69,593 blocks cocaine-induced enhancement of brain stimulation
reward. Biol. Psychiatry 64, 982−988.
(24) Potter, D. N., Damez-Werno, D., Carlezon, W. A., Jr., Cohen, B.
M., and Chartoff, E. H. (2011) Repeated exposure to the kappa-opioid
receptor agonist salvinorin A modulates extracellular signal-regulated
kinase and reward sensitivity. Biol. Psychiatry 70, 744−753.
ABBREVIATIONS
■
DOR, delta opioid receptor; KOR, kappa opioid receptor;
MOR, mu opioid receptor; NMDA, N-methyl-D-aspartate
receptor; σ, sigma; ICSS, intracranial self-stimulation; DX,
dextrorphan; DXM, dextromethorphan; PCP, phencyclidine;
mPFC, medial prefrontal cortex; NR1, subunit of NMDA
receptor; TLR, toll-like receptor
REFERENCES
■
(1) McCurdy, C. R., and Prisinzano, T. E. (2010) Opioid Receptor
Ligands. In Burger’s Medicinal Chemistry, Drug Discovery, and
Development (Abraham, D. J., and Rotella, D. P., Eds.), seventh ed.,
John Wiley and Sons, Inc., New York.
(2) Pentney, R. J. W. (1991) Gratton, Effects of Local Delta and Mu
Opioid Receptor Activation on Basal and Stimulated Dopamine
Release in Striatum and Nucleus Accumbens of Rat: An In Vivo
Electrochemical Study. Neuroscience 45, 95−102.
(3) Shippenberg, T. S. (2009) The dynorphin/kappa opioid receptor
system: a new target for the treatment of addiction and affective
disorders? Neuropsychopharmacology 34, 247.
(4) Glick, S. D., Maisonneuve, I. M., Dickinson, H. A., and Kitchen,
B. A. (2001) Comparative effects of dextromethorphan and dextro-
rphan on morphine, methamphetamine, and nicotine self-admin-
istraion in rats. Eur. J. Pharmacol. 422, 87−90.
(5) Chen, L., and Huang, L.-Y. M. (1991) Sustained Potentiation of
NMDA Receptor-Mediated Glutamate Responses Through Activation
of Protein Kinase C by a μ Opioid. Neuron 7, 319−326.
(6) Elliott, K., Kest, B., Man, A., Kao, B., and Inturrisi, C. E. (1995)
N-Methyl-D-aspartate (NMDA) Receptors, Mu and Kappa Opioid
Tolerance, and Perspectives on New Analgesic Drug Development.
Neuropsychopharmacology 13 (4), 347−356.
(7) Svingos, A. L., and Colago, E. E. O. (2002) k-Opioid and NMDA
glutamate receptors are differentially targeted within rat medial
prefrontal cortex. Brain Res. 946, 262−271.
(8) Trujillo, K. A. (1995) Effects of Noncompetitive N-Methyl-D-
aspartate Receptor Antagonists on Opiate Tolerance and Physical
Dependence. Neuropsychopharmacology 13 (4), 301−307.
(9) Zapata, A., Gasior, M., Geter-Douglass, B., Tortella, F. C.,
Newman, A. H., and Witkin, J. M. (2003) Attenuation of the stimulant
and convulsant effects of cocaine by 17-substituted-3-hydroxy and 3-
alkoxy derivatives of dextromethorphan. Pharmacol., Biochem. Behav.
74, 313−323.
(10) Iijima, I., Minamikawa, J.-I., Jacobson, A. E., Brossi, A., Rice, K.
C., and Klee, W. (1978) Studies in the (+)-Morphinan Series. 5.
Synthesis and Biological Properties of (+)-Naloxone. J. Med. Chem. 21
(4), 398−400.
(11) Chatterjie, N., Alexander, G. J., Sechzer, J. A., and Lieberman, K.
W. (1996) Prevention of Cocaine-Induced Hyperactivity by a
Naloxone Isomer with no Opiate Antagonist Activity. Neurochem.
Res. 21 (6), 691−693.
F
dx.doi.org/10.1021/cn400205z | ACS Chem. Neurosci. XXXX, XXX, XXX−XXX